Using radiofrequency ablation to treat pancreatic neuroendocrine tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy of radiofrequency ablation (RFA) for treating grade 1 nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) that are 2 cm or smaller. Patients will undergo 1 to 3 RFA sessions based on their treatment response and will be monitored for 5 years to assess their clinical outcomes, quality of life, and any complications. The aim is to provide a less costly and anxiety-inducing alternative to the current monitoring practices for these tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI;
* Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (HEE) with Ki67\<3%,
* Non-secretory lesion.
* Homogeneous HEE contrast taking;
* No positron emission tomography (PET) FDG binding to the pancreatic mass;
* Lesion \<20mm on conventional imaging at 6 months monitoring;
* Age 18 to 80 years inclusive;
* Patient in good general condition, World Health Organization \[0-1\];
* Signed consent to participate;
* Affiliation to healthcare insurance system or beneficiary of this regimen.

Exclusion Criteria:

* Pregnant or likely to become pregnant (without effective contraception) or breastfeeding ;
* A person in an emergency situation or deprived of liberty or placed under the authority of a tutor.
* Life expectancy \< 1 year;
* Severe hemostasis disorders;
* Pancreatic and/or biliary ductal dilation;
* Lesion considered to be adjacent to the pancreatic duct and/or bile duct;
* Node extension and/or metastatic disease;
* Patient being managed for another malignant lesion which is progressive or under treatment.

Where it's running

• Institut Paoli Calmettes
  Marseille, France Recruiting

Study contacts

• Principal investigator: Fabrice CAILLOL, MD — Paoli Calmettes Institute
• Study coordinator: Jihane PAKRADOUNI
• Email: drci.up@ipc.unicancer.fr
• Phone: +33491223778

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating the impact of somatostatin analogues on tumor dose during radionuclide therapy

  This study is testing if stopping or continuing long-acting somatostatin treatment affects how well radionuclide therapy works for adults with neuroendocrine tumors.

  Recruiting Phase 2/3 The Netherlands Cancer Institute · Amsterdam · NCT06855095

• Comparing two doses of Everolimus for treating neuroendocrine tumors

  This study is testing whether a lower dose of Everolimus can effectively treat patients with advanced neuroendocrine tumors while causing fewer side effects compared to a higher dose.

  Recruiting at 2 sites Phase 2 AC Camargo Cancer Center · São Paulo, São Paulo and 1 other locations · NCT06472388

• Customized Lutetium-177 treatment for neuroendocrine tumors

  This study is testing if a personalized dose of Lutetium-177 can improve treatment results for adults with hard-to-treat neuroendocrine tumors compared to standard treatment.

  Recruiting Phase 2 University of Iowa · Iowa City, Iowa · NCT06395402

• Exploring new biomarkers for diagnosing and treating neuroendocrine tumors

  This study is testing new ways to diagnose and treat neuroendocrine tumors by looking at blood samples to see if they can provide better information about the cancer.

  Recruiting University of Roma La Sapienza · Rome, Italy · NCT04464122

• Combination therapy for Grade 2 liver-dominant neuroendocrine tumors

  This study is testing a new combination treatment of two drugs followed by a special radiation therapy to see if it helps people with Grade 2 liver-dominant neuroendocrine tumors live longer without their cancer getting worse.

  Recruiting Phase 2 Abramson Cancer Center at Penn Medicine · La Jolla, California and 4 other locations · NCT04339036

• PRRT alone versus PRRT plus chemotherapy for gastroenteropancreatic neuroendocrine tumors

  This test sees if adding capecitabine–temozolomide chemotherapy to Lutetium‑177 DOTATATE PRRT helps adults with advanced gastroenteropancreatic neuroendocrine tumors live longer without the cancer getting worse.

  Recruiting at 2 sites Phase 3 Tata Memorial Hospital · Mumbai, Maharashtra and 1 other locations · NCT07185672

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.